A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Active, not recruiting · Phase 1, Phase 2 · NCT04626635
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $5.3M
- U.S. investigators named
- 19
- Sites paid
- 17
- Planned or actual enrollment
- 548
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- REGN7075 (drug), Cemiplimab (drug), Platinum-based doublet chemotherapy (drug), Bevacizumab (drug), Trifluridine-tipiracil (drug)
- Dates
- Started 2020-12-21; completion 2027-03-05
- Results posted
- Not yet
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at …
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $5.3M in research payments for this study in 2025 (447 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David Berz, MD, PHD, MPH Hematology & Oncology · Los Angeles, CA
- Joel R. Hecht, MD Hematology & Oncology · Los Angeles, CA
- Bridget Keenan Medical Oncology · San Francisco, CA
- Erin L. Schenk, MD Medical Oncology · Aurora, CO
- Thomas J. George JR., MD Hematology & Oncology · Gainesville, FL
- Douglas E. Laux, MD Hematology & Oncology · Iowa City, IA
- Oana C. Danciu, M.D. Hematology & Oncology · Chicago, IL
- Xiuning Le, M.D. Specialist · Boston, MA
- Nehal J. Lakhani, M.D. Hematology & Oncology · Grand Rapids, MI
- Eugenia Girda, M.D. Gynecologic Oncology · New Brunswick, NJ
- Sanjay Goel, MD Medical Oncology · New Brunswick, NJ
- Neil H. Segal, M.D.,PH.D. Specialist · New York, NY
- Davendra P. Sohal, MD, MPH Hematology & Oncology · Cincinnati, OH
- Anthony J. Olszanski, M.D. Medical Oncology · Philadelphia, PA
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- Lawrence Fong, MD Hematology & Oncology · Seattle, WA
- Cristina P. Rodriguez, MD Hematology & Oncology · Seattle, WA
- Stuart Wong, MD Medical Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $1.3M
- Valkyrie Clinical Trials Inc $942,306
- University of Iowa Hospital & Clinics, IA $638,670
- Rutgers the State University of New Jersey $540,220
- Ut MD Anderson Cancer Center $485,735
- University of Cincinnati $343,522
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $317,503
- Sarah Cannon Research Institute LLC $220,850
- University of Florida $131,648
- The Medical College of Wisconsin Inc $114,950
- Ronald Reagan UCLA Medical Center, CA $89,047
- South Texas Accelerated Research Therapeutics LLC $44,792
- Regents of the University of Colorado $40,626
- University of Illinois Hospital and Clinics, IL $39,363
- Start Midwest LLC $38,623
- University of Washington Medical Ctr, WA $27,353
- $9,590
- Institute for Cancer Research $8,016
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.